文献速递神经免疫

髓鞘少突胶质细胞糖蛋白抗体相关疾病的诊断:国际MOGAD专家组拟议标准

Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
PubMed 文献 · Lancet Neurol · 2023-01-24

基于广泛文献复习和结构化共识流程,国际MOGAD专家组提出髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)的诊断标准,以MOG-IgG阳性为核心标准。MOGAD典型表现为急性播散性脑脊髓炎、视神经炎或横贯性脊髓炎,较少表现为大脑皮质脑炎、脑干或小脑表现,病程可为单相或复发型。该拟议标准需验证,但可能改善MOGAD的识别。

要点

  • MOGAD诊断以MOG-IgG阳性为核心标准,需结合典型临床表现并排除多发性硬化等诊断。
  • MOG-IgG细胞法检测对诊断准确性很重要;并非所有多发性硬化患者都需筛查MOG-IgG。
  • 该拟议标准需验证,但可能有助于识别MOGAD患者、定义长期结局和优化临床试验纳入标准。

核心结论

  • 基于广泛文献复习和结构化共识流程,提出以MOG-IgG阳性为核心标准的MOGAD诊断标准,该标准需验证但可能改善MOGAD识别。

研究设计与样本

  • 国际MOGAD专家组基于广泛文献复习和结构化共识流程提出拟议诊断标准。

主要发现

  • MOGAD典型与急性播散性脑脊髓炎、视神经炎或横贯性脊髓炎相关,较少与大脑皮质脑炎、脑干或小脑表现相关。
  • MOGAD可表现为单相或复发型病程,MOG-IgG细胞法检测对诊断准确性很重要。
  • 需排除多发性硬化等诊断,但并非所有多发性硬化患者都应筛查MOG-IgG。

关键数值与推荐

  • 拟议标准以MOG-IgG阳性为核心诊断标准,需结合典型临床表现并排除多发性硬化等诊断。
  • MOG-IgG细胞法检测对诊断准确性很重要;并非所有多发性硬化患者都应筛查MOG-IgG。

临床怎么用

  • 原文未据此给出推荐;作者提出该拟议诊断标准需验证,但可能改善MOGAD识别,有助于定义长期临床结局、优化临床试验纳入标准和识别复发型与单相病程的预测因素。

局限性

  • 原文指出这些拟议诊断标准需要验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder. Based on an extensive literature review and a structured consensus process, we propose diagnostic criteria for MOG antibody-associated disease (MOGAD) in which the presence of MOG-IgG is a core criterion. According to our proposed criteria, MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis, and is less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations. MOGAD can present as either a monophasic or relapsing disease course, and MOG-IgG cell-based assays are important for diagnostic accuracy. Diagnoses such as multiple sclerosis need to be excluded, but not all patients with multiple sclerosis should undergo screening for MOG-IgG. These proposed diagnostic criteria require validation but have the potential to improve identification of individuals with MOGAD, which is essential to define long-term clinical outcomes, refine inclusion criteria for clinical trials, and identify predictors of a relapsing versus a monophasic disease course.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023. PMID: 36706773. doi:10.1016/S1474-4422(22)00431-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。